BTIG Maintains Buy on Globus Medical, Raises Price Target to $72
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman maintains a Buy rating on Globus Medical (NYSE:GMED) and raises the price target from $63 to $72.
May 29, 2024 | 11:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Ryan Zimmerman maintains a Buy rating on Globus Medical and raises the price target from $63 to $72.
The raised price target and maintained Buy rating from a reputable analyst are likely to positively impact investor sentiment and drive short-term price appreciation for GMED.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100